SCHEMBL4157147

SCHEMBL4157147

Cc1cccc(-c2cc(-c3cccc(C=O)c3)c3cc[nH]c3n2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 7/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C8 P10632 1/20 0.50
CDK8 P49336 1/20 0.47
AXL P30530 1/20 0.41
TGFBR2 P37173 2/20 0.38
CCR1 P32246 1/20 0.37
CCR8 P51685 1/20 0.37
BRD4 O60885 1/20 0.36
NUDT1 P36639 1/20 0.36
PRKCI P41743 1/20 0.36
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
CYP2A6 P11509 1/20 0.35
IKBKB O14920 1/20 0.35
CHUK O15111 1/20 0.35
PAK1 Q13153 1/20 0.34
CFD P00746 1/20 0.34
CCNK O75909 1/20 0.34
CDK12 Q9NYV4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3796603 0.91 CDK8 (0.49) TGFBR1CYP3A4CYP2C8CDK8AXL
SCHEMBL4171887 0.89 TGFBR1 (0.51) TGFBR1CYP3A4CYP2C8CDK8TGFBR2
SCHEMBL4153879 0.83 TGFBR1 (0.47) TGFBR1CYP3A4CYP2C8CDK8AXL
SCHEMBL3796791 0.81 TGFBR1 (0.47) TGFBR1CYP3A4CYP2C8CDK8TGFBR2
SCHEMBL4168756 0.79 TGFBR1 (0.58) TGFBR1CYP3A4CYP2C8TGFBR2NUDT1
SCHEMBL3803436 0.75 TGFBR1 (0.48) TGFBR1CYP3A4CYP2C8TGFBR2CCR1
SCHEMBL4151363 0.74 TGFBR1 (0.53) TGFBR1CYP3A4CYP2C8TGFBR2CCR1
SCHEMBL4153898 0.74 TGFBR1 (0.53) TGFBR1CYP3A4CYP2C8TGFBR2CCR1
SCHEMBL857778 0.74 NUDT1 (0.64) CDK8AXLBRD4NUDT1PRKCI
SCHEMBL3794751 0.74 TGFBR1 (0.52) TGFBR1CYP3A4CYP2C8TGFBR2CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314112-B2 Pyrrolopyrimidines and pyrrolopyridines NOVARTIS AG (CH) 2012-11-20 US disclosed
US-20090181941-A1 Pyrrolopyrimidines and Pyrrolopyridines NOVARTIS AG (CH) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181941-A1 Pyrrolopyrimidines and Pyrrolopyridines ALK, ACVR1, PTPN4 TGFBR1 128/4885CYP3A4 111/4885CYP2C8 1297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.